Kane Biotech (KNE)
KNE · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Biofilm Disruptionsrc
Signal Snapshot
0
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia. — J Psychiatr Res (2026) PMID 42628238
- Sex-Stratified Outcomes of Drug-Eluting Resorbable Scaffolds Versus Balloon Angioplasty for Below-the-Knee Revascularization: Insights From the LIFE-BTK Trial. — J Soc Cardiovasc Angiogr Interv (2026) PMID 42626061
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Kane Biotech.
Full KNE Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.